(Q37387962)

20 August 2017

1 reference

title

New options for early treatment of multiple sclerosis (English)

1 reference

20 August 2017

0 references

Mar Tintoré

1

0 references

publication date

1 February 2009

1 reference

Journal of the Neurological Sciences

20 August 2017

1 reference

20 August 2017

277 Suppl 1

1 reference

20 August 2017

S9-S11

1 reference

Rationale for early intervention with immunomodulatory treatments

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

The pathological evolution of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2809%2970004-8

10.1016/S0022-510X(09)70004-8

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19200870